# Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

> **NCT03911453** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Arizona** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT03911453
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-19
- **Primary completion:** 2021-07-16
- **Final completion:** 2021-07-16
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03911453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03911453, "Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03911453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*